Zhong Huiqiu, Luo Xiaojiang
Department of Otorhinolaryngology Head and Neck Surgery, Jiangxi Provincial People's Hospital, Nanchang 330006, P.R. China.
Department of Gastrointestinal Surgery, Jiangxi Provincial People's Hospital, Nanchang 330006, P.R. China.
Iran J Public Health. 2021 Sep;50(9):1789-1795. doi: 10.18502/ijph.v50i9.7051.
We aimed to investigate the serum concentration of dihydropyrimidinase-like 3 (DPYSL3) in patients with gastric cancer and its clinical significance.
Seventy four patients with gastric cancer from Wuhan Central Hospital, Tongji Medical College, Huazhong University of Science and Technology, China from October 2018 to April 2019 were selected as the case group. Sixty patients with normal gastric mucosa or mild non-atrophic gastritis were selected as the control group. Serum DPYSL3, CA72-4 and CEA concentrations were measured in both groups.
The serum DPYSL3 concentration in the case group was significantly higher than that in the healthy control group (22.04±9.22 vs. 8.36±4.19 μg/L, <0.001). The serum DPYSL3 concentration in patients with advanced gastric cancer was significantly higher than that in early gastric cancer (27.09±9.12 vs. 13.04±8.22 μg/L, <0.01); serum DPYSL3 concentration was significantly correlated with tumor size, TNM stage and differentiation (<0.05). When the cutoff value was 20.98 μg/L, the serum DPYSL3 concentration could differentiate the gastric cancer with ROC 0.882 (95% CI: 0.828-0.937) with sensitivity and specificity of 75% and 94%, respectively. Serum CA72-4 concentration could differentiate the gastric cancer from health controls with ROC 0.812 (95% CI: 0.734-0.834), serum CEA concentration could differentiate gastric cancer with ROC 0.612 (95% CI: 0.534 ∼ 0.634). The serum concentrations of DPYSL3, CA72-4 and CEA in gastric cancer patients were increased compared to health controls.
Three serological markers have complementary diagnostic value for gastric cancer. Serum DPYSL3 is a new potential molecular marker for gastric cancer.
我们旨在研究胃癌患者血清中双氢嘧啶酶样3（DPYSL3）的浓度及其临床意义。
选取2018年10月至2019年4月来自中国华中科技大学同济医学院附属武汉中心医院的74例胃癌患者作为病例组。选取60例胃黏膜正常或轻度非萎缩性胃炎患者作为对照组。检测两组患者血清中DPYSL3、CA72-4和CEA的浓度。
病例组血清DPYSL3浓度显著高于健康对照组（22.04±9.22 vs. 8.36±4.19 μg/L，<0.001）。进展期胃癌患者血清DPYSL3浓度显著高于早期胃癌患者（27.09±9.12 vs. 13.04±8.22 μg/L，<0.01）；血清DPYSL3浓度与肿瘤大小、TNM分期及分化程度显著相关（<0.05）。当截断值为20.98 μg/L时，血清DPYSL3浓度诊断胃癌的ROC为0.882（95%CI：0.828-0.937），敏感性和特异性分别为75%和94%。血清CA72-4浓度诊断胃癌与健康对照的ROC为0.812（95%CI：0.734-0.834），血清CEA浓度诊断胃癌的ROC为0.612（95%CI：0.534～0.634）。与健康对照相比，胃癌患者血清中DPYSL3、CA72-4和CEA浓度均升高。
三种血清学标志物对胃癌具有互补的诊断价值。血清DPYSL3是一种新的潜在胃癌分子标志物。
